title: Clinical features and outcome in hospitalized heart failure in Japan (from the ATTEND Registry).
abstract: BACKGROUND
  Hospitalized heart failure (HHF) is a critical issue in Japan. To improve its management and outcomes, the clinical features, in-hospital management, and outcomes should be analyzed to improve the guidelines for HHF.
  
  
  RESULTS
  The acute decompensated heart failure syndromes (ATTEND) registry is the largest study of HHF in Japan. The present report covers the clinical features and in-hospital management of HHF patients. The data from 4,842 enrolled patients have demonstrated that most Japanese HHF patients are elderly, with new onset, and a history of hypertension and orthopnea on admission. During hospitalization, furosemide and carperitide were commonly used and the length of stay was extremely long (mean 30 days), with 6.4% in-hospital mortality.
  
  
  CONCLUSIONS
  The findings of the present study suggest the following: (1) the focus for hypertensive elderly and diabetic patients should be on primary prevention of HHF,(2) more intensive management with noninvasive positive pressure ventilation should be performed at the urgent stage, (3) it is necessary to clarify the clinical benefit of carperitide and angiotensin-receptor blockers, because they are commonly used in Japan, and (4) it is necessary to clarify the relationship between in-hospital mortality and length of stay from the viewpoint of both outcome and cost of patient care.
authors.affiliation: Internal Medicine and Cardiology, Nippon Medical School Musashi-Kosugi Hospital, Kawasaki, Japan. nms-ns@nms.ac.jp
authors.forename: Naoki
authors.initials: N
authors.lastname: Sato
authors.forename: Katsuya
authors.initials: K
authors.lastname: Kajimoto
authors.forename: Takehiko
authors.initials: T
authors.lastname: Keida
authors.forename: Masayuki
authors.initials: M
authors.lastname: Mizuno
authors.forename: Yuichiro
authors.initials: Y
authors.lastname: Minami
authors.forename: Dai
authors.initials: D
authors.lastname: Yumino
authors.forename: Kuniya
authors.initials: K
authors.lastname: Asai
authors.forename: Koji
authors.initials: K
authors.lastname: Murai
authors.forename: Ryo
authors.initials: R
authors.lastname: Muanakata
authors.forename: Toshiyuki
authors.initials: T
authors.lastname: Aokage
authors.forename: Yasushi
authors.initials: Y
authors.lastname: Sakata
authors.forename: Kyoichi
authors.initials: K
authors.lastname: Mizuno
authors.forename: Teruo
authors.initials: T
authors.lastname: Takano
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D057911:Angiotensin Receptor Antagonists / Q000008:administration & dosage*; D009320:Atrial Natriuretic Factor / Q000008:administration & dosage*; D048909:Diabetes Complications / Q000188:drug therapy / Q000401:mortality; D005260:Female; D005665:Furosemide / Q000008:administration & dosage*; D006333:Heart Failure / Q000188:drug therapy* / Q000401:mortality*; D017052:Hospital Mortality; D006801:Humans; D006973:Hypertension / Q000188:drug therapy / Q000401:mortality; D007564:Japan / Q000453:epidemiology; D007902:Length of Stay; D008297:Male; D011446:Prospective Studies; D012042:Registries; D049994:Sodium Potassium Chloride Symporter Inhibitors / Q000008:administration & dosage*
chemical_list: D057911:Angiotensin Receptor Antagonists; C472955:NPPA protein, human; D049994:Sodium Potassium Chloride Symporter Inhibitors; D005665:Furosemide; D009320:Atrial Natriuretic Factor